BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15853706)

  • 21. New progesterone derivatives as inhibitors of 5alpha-reductase enzyme and prostate cancer cell growth.
    Cabeza M; Bratoeff E; Heuze I; Rojas A; Terán N; Ochoa M; Ramírez-Apan T; Ramírez E; Pérez V; Gracia I
    J Enzyme Inhib Med Chem; 2006 Aug; 21(4):371-8. PubMed ID: 17059168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fungi test for evaluation of new antiandrogenic molecule.
    Cabeza M; Quiroz A; Bratoeff E; Heuze I; Ramírez E; Murillo E
    Proc West Pharmacol Soc; 2000; 43():29-30. PubMed ID: 11056949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The enzyme and inhibitors of 4-ene-3-oxosteroid 5 alpha-oxidoreductase.
    Li X; Chen C; Singh SM; Labrie F; Labire F [corrected to Labrie F]
    Steroids; 1995 Jun; 60(6):430-41. PubMed ID: 7676475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors.
    Bratoeff E; Cabeza M; Pérez-Ornelas V; Recillas S; Heuze I
    J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):275-81. PubMed ID: 18644453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative binding affinity of novel steroids to androgen receptors in hamster prostate.
    Cabeza M; Heuze I; Sánchez M; Bratoeff E; Ramírez E; Rojas A; Orozco A; Mungía A; Agustín G; Cuatepotzo L; Gonzalez C; Palma S; Padilla D; Perez V; Jimenez G
    J Enzyme Inhib Med Chem; 2005 Aug; 20(4):357-64. PubMed ID: 16206830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and pharmacological evaluation of new progesterone esters as 5alpha-reductase inhibitors.
    Ramírez E; Cabeza M; Bratoeff E; Heuze I; Pérez V; Valdez D; Ochoa M; Teran N; Jimenez G; Ramírez T
    Chem Pharm Bull (Tokyo); 2005 Dec; 53(12):1515-8. PubMed ID: 16327180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds.
    Nnane IP; Kato K; Liu Y; Long BJ; Lu Q; Wang X; Ling YZ; Brodie A
    Endocrinology; 1999 Jun; 140(6):2891-7. PubMed ID: 10342882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
    George FW
    Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
    J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel 17 substituted pregnadiene derivatives as 5 alpha-reductase inhibitors and their binding affinity for the androgen receptor.
    Cabeza M; Flores E; Heuze I; Sánchez M; Bratoeff E; Ramírez E; Francolugo VA
    Chem Pharm Bull (Tokyo); 2004 May; 52(5):535-9. PubMed ID: 15133203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of 17beta-(N-alkyl/arylformamido) and 17beta-[(N-alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors in the hamster flank organ and ear.
    Chen C; Li X; Singh SM; Labrie F
    J Invest Dermatol; 1998 Aug; 111(2):273-8. PubMed ID: 9699729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
    Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
    J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells.
    Festuccia C; Angelucci A; Gravina GL; Muzi P; Vicentini C; Bologna M
    J Cancer Res Clin Oncol; 2005 Apr; 131(4):243-54. PubMed ID: 15650886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New steroidal lactones as 5α-reductase inhibitors and antagonists for the androgen receptor.
    Garrido M; Bratoeff E; Bonilla D; Soriano J; Heuze Y; Cabeza M
    J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):367-73. PubMed ID: 21782943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo.
    Nnane IP; Njar VC; Liu Y; Lu Q; Brodie AM
    J Steroid Biochem Mol Biol; 1999 Dec; 71(3-4):145-52. PubMed ID: 10659703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new look at the 5alpha-reductase inhibitor finasteride.
    Finn DA; Beadles-Bohling AS; Beckley EH; Ford MM; Gililland KR; Gorin-Meyer RE; Wiren KM
    CNS Drug Rev; 2006; 12(1):53-76. PubMed ID: 16834758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assignment of anabolic-androgenic and antiandrogenic properties to some chlorine-substituted steroids on the basis of their binding characteristics to the androgen receptor of the rat seminal vesicle.
    Zakár T; Kaufmann G; Tóth M
    Exp Clin Endocrinol; 1986 Jul; 87(2):133-41. PubMed ID: 3758193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
    Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
    Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a new gas chromatography-mass spectrometry (GC-MS) methodology for the evaluation of 5α-reductase activity.
    Amaral C; Cunha SC; Fernandes JO; Tavares da Silva E; Roleira FM; Teixeira N; Correia-da-Silva G
    Talanta; 2013 Mar; 107():154-61. PubMed ID: 23598206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.